Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab with or without temozolomide plus adjuvant nodal radiotherapy in resected stage IIIC-IIID acral melanoma
ChiCTR2300071381Phase 2Recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Jul 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of camrelizumab and temozolomide in acral lentiginous melanoma (ALM) (2 arms), sponsored by Fudan University Shanghai Cancer Center. Primary endpoint: 1-year relapse-free survival rate. Started Jul 2022; status: recruiting.
02
Drugs
camrelizumabtemozolomide
03
Conditions
acral lentiginous melanoma (ALM)
Beyond the preview
Go deeper on ChiCTR2300071381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300071381.